Replies to post #4726 on Dendreon Corp fka DNDNQ

[rancherho]

I misunderstood this statement:"Even if the MS for the GVAX arm is 30.7 months, there is still a 20% chance it won't be stat sig superior to Tax." Assuming the MS for GVAX is 30.7 months and the Taxotere MS arm is 23 months and where there are 300 patients in each arm, I'm confused as to why GVAX wouldn't be stat significant. It would seem that if those numbers held, the Vital-1 trial would have more power to be stat significant than the 500 patient 9902b trial based on the 4.3 month increase in MS of the integrated 147 patients of the Provenge 9901 and 9902a trials.